
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1523039/publications.pdf Version: 2024-02-01



Ηικλαιι Ησαι

#	Article	IF	CITATIONS
1	Elderly bipolar disorder with hyperthyroidism during longâ€ŧerm lithium treatment: A case report. Bipolar Disorders, 2022, 24, 90-90.	1.9	2
2	Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Medicine, 2022, 89, 23-30.	1.6	16
3	Association between the examination rate of treatmentâ€resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacology Reports, 2022, 42, 3-9.	2.3	14
4	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian Journal of Psychiatry, 2022, 69, 103007.	2.0	12
5	Successful treatment for major depressive disorder with psychotic features with addition of asenapine on escitalopram. Psychogeriatrics, 2022, 22, 413-414.	1.2	0
6	Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacology Reports, 2022, 42, 221-225.	2.3	12
7	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. World Journal of Biological Psychiatry, 2022, 23, 785-793.	2.6	6
8	A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open, 2022, 8, e83.	0.7	11
9	Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics. Frontiers in Psychiatry, 2022, 13, .	2.6	9
10	Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. International Journal of Neuropsychopharmacology, 2022, 25, 818-826.	2.1	11
11	Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia. CNS Spectrums, 2021, 26, 658-663.	1.2	6
12	Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry, 2021, 26, 118-133.	7.9	71
13	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacology Reports, 2021, 41, 199-206.	2.3	17
14	Editorial: How to Help Employees Returning to Work Following Depression. Frontiers in Psychiatry, 2021, 12, 714589.	2.6	1
15	Psychological training to improve psychosocial function in patients with major depressive disorder: A randomised clinical trial. Psychiatry Research, 2021, 300, 113906.	3.3	8
16	Prospects for CNPT. Clinical Neuropsychopharmacology and Therapeutics, 2021, 12, 11-11.	0.3	1
17	Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of firstâ€episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms. Human Psychopharmacology, 2021, 36, e2804.	1.5	5
18	Doxazosin improved COVID-19 associated nightmare in a patient with major depressive disorder: a case report with a positive rechallenge. International Clinical Psychopharmacology, 2021, 36, 221-223.	1.7	1

#	Article	IF	CITATIONS
19	Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian Journal of Psychiatry, 2021, 63, 102744.	2.0	28
20	No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. European Neuropsychopharmacology, 2021, 53, 34-46.	0.7	22
21	Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia. International Clinical Psychopharmacology, 2020, 35, 89-97.	1.7	4
22	Unmet needs of patients with major depressive disorder – Findings from the † <scp>E</scp> ffectiveness of <scp>G</scp> uidelines for <scp>D</scp> issemination and <scp>E</scp> ducation in <scp>P</scp> sychiatric <scp>T</scp> reatment (<scp>EGUIDE</scp>)' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences, 2020, 74, 667-669.	1.8	20
23	Predictors of return to work success among Japanese employees with major depressive disorder. Psychiatry Research, 2020, 291, 113209.	3.3	3
24	Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status. Brain, Behavior, and Immunity, 2020, 88, 242-251.	4.1	10
25	Prescription patterns in patients with schizophrenia in Japan: Firstâ€quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)―project. Neuropsychopharmacology Reports, 2020, 40, 281-286.	2.3	32
26	<p>Assessment of current clinical practices for major depression in Japan using a web-based questionnaire</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2821-2832.	2.2	3
27	Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the †Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences. 2019. 73. 642-648.	1.8	35
28	Risk factors for further sick leave among Japanese workers returning to work after an episode of major depressive disorder: a prospective follow-up study over 1 year. BMJ Open, 2019, 9, e029705.	1.9	14
29	Deciphering reward-based decision-making in schizophrenia: A meta-analysis and behavioral modeling of the Iowa Gambling Task. Schizophrenia Research, 2019, 204, 7-15.	2.0	23
30	Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacopsychiatry, 2019, 52, 52-62.	3.3	22
31	Immunoglobulin genotypes and cognitive functions in schizophrenia. Immunogenetics, 2018, 70, 67-72.	2.4	6
32	Effect of single caffeine intake on neuropsychological functions in healthy volunteers: A double-blind placebo-controlled study. PLoS ONE, 2018, 13, e0202247.	2.5	13
33	Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. Frontiers in Psychiatry, 2018, 9, 74.	2.6	12
34	The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients. Frontiers in Psychiatry, 2018, 9, 232.	2.6	14
35	Social cognition and metacognition contribute to accuracy for self-evaluation of real-world functioning in patients with schizophrenia. Schizophrenia Research, 2018, 202, 426-428.	2.0	7
36	Cognitive Deficits in the THINC-Integrated Tool (THINC-it) Are Associated With Psychosocial Dysfunction in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2018, 80, .	2.2	14

#	Article	IF	CITATIONS
37	Relationship between the hippocampal shape abnormality and serum cortisol levels in first-episode and drug-naÃ ⁻ ve major depressive disorder patients. Depression and Anxiety, 2017, 34, 401-409.	4.1	21
38	The Contactless Vital Sensing System Precisely Reflects R-R Interval in Electrocardiograms of Healthy Subjects. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 514-515.	1.2	6
39	The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale. Therapeutic Advances in Psychopharmacology, 2017, 7, 11-16.	2.7	1
40	Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World Journal of Biological Psychiatry, 2017, 18, 401-408.	2.6	34
41	Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 568.	4.1	12
42	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 437-441.	2.2	8
43	Marked Improvement of Meige Syndrome in a Japanese Male Patient with Schizophrenia After Switching from Risperidone to Paliperidone: A Case Report. Journal of UOEH, 2016, 38, 233-236.	0.6	7
44	Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2279-2281.	2.2	5
45	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. PLoS ONE, 2016, 11, e0150712.	2.5	18
46	Decreased Activity at the Time of Return to Work Predicts Repeated Sick Leave in Depressed Japanese Patients. Journal of Occupational and Environmental Medicine, 2016, 58, e56-e57.	1.7	3
47	Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale–Japanese version. Schizophrenia Research: Cognition, 2016, 6, 9-14.	1.3	30
48	Does subjective sleep quality improve by a walking intervention? A real-world study in a Japanese workplace. BMJ Open, 2016, 6, e011055.	1.9	22
49	Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia. Annals of General Psychiatry, 2016, 15, 1.	2.7	13
50	Electroconvulsiveâ€ŧherapyâ€associated neutropenia in treatmentâ€resistant schizophrenia: Three case reports. Psychiatry and Clinical Neurosciences, 2015, 69, 504-504.	1.8	1
51	Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2015, 11, 967.	2.2	7
52	Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study. Neuropsychiatric Disease and Treatment, 2014, 10, 2315.	2.2	9
53	Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task. Frontiers in Behavioral Neuroscience, 2014, 8, 417.	2.0	24
54	Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. Neuropsychiatric Disease and Treatment, 2014, 10, 527.	2.2	28

#	Article	IF	CITATIONS
55	Hiccups Associated With Switching From Olanzapine to Aripiprazole in a Patient With Paranoid Schizophrenia. Clinical Neuropharmacology, 2014, 37, 88-89.	0.7	14
56	Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. Therapeutic Advances in Psychopharmacology, 2014, 4, 123-129.	2.7	8
57	A successful case of dose reduction in etizolam dependence using fine granules: a case report. International Medical Case Reports Journal, 2014, 7, 121.	0.8	3
58	Serum proBDNF/BDNF and response to fluvoxamine in drug-naÃ ⁻ ve first-episode major depressive disorder patients. Annals of General Psychiatry, 2014, 13, 19.	2.7	25
59	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. Psychiatry Research, 2014, 215, 803-805.	3.3	3
60	Abnormal White Matter Integrity in the Corpus Callosum among Smokers: Tract-Based Spatial Statistics. PLoS ONE, 2014, 9, e87890.	2.5	35
61	Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs. Psychiatry Investigation, 2014, 11, 84.	1.6	12
62	Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience, 2014, 12, 37-40.	2.0	10
63	Plasma levels of interleukinâ€6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Human Psychopharmacology, 2013, 28, 466-470.	1.5	53
64	Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report. General Hospital Psychiatry, 2013, 35, 103.e7-103.e9.	2.4	10
65	Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research, 2013, 47, 1843-1848.	3.1	34
66	Current smoking rate in patients with psychiatric disorders in Japan: Questionnaire survey. Psychiatry Research, 2013, 210, 268-273.	3.3	3
67	Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus. Human Psychopharmacology, 2013, 28, 198-202.	1.5	7
68	Serum Brain–Derived Neurotrophic Factor Levels at 6 Months After Remission Are Not Associated With Subsequent Depressive Episodes. Journal of Clinical Psychopharmacology, 2013, 33, 142-143.	1.4	2
69	Herbal Medicine (Shakuyaku-kanzo-to) Improves Olanzapine-Associated Hyperprolactinemia. Journal of Clinical Psychopharmacology, 2013, 33, 122-123.	1.4	5
70	The Effects of a Walking Intervention on Depressive Feelings and Social Adaptation in Healthy Workers. Journal of UOEH, 2013, 35, 1-8.	0.6	8
71	Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review. Clinical Psychopharmacology and Neuroscience, 2013, 11, 34-38.	2.0	13
72	Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. International Journal of Psychiatry in Clinical Practice, 2012, 16, 138-142.	2.4	22

#	Article	IF	CITATIONS
73	Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectrums, 2012, 17, 155-163.	1.2	39
74	Plasma Levels of Metabolites of Catecholamine in Nicotine-Dependent Patients Treated With Varenicline. Nicotine and Tobacco Research, 2012, 14, 486-489.	2.6	2
75	Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 355-357.	4.8	21
76	Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia. Neuropsychiatric Disease and Treatment, 2012, 8, 119.	2.2	52
77	The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. Journal of Psychiatric Research, 2012, 46, 757-761.	3.1	34
78	Aripiprazole altered plasma levels of brainâ€derived neurotrophic factor and catecholamine metabolites in firstâ€episode untreated Japanese schizophrenia patients. Human Psychopharmacology, 2012, 27, 33-38.	1.5	34
79	Plasma levels of catecholamine metabolites and serum levels of brain-derived neurotorophic factor in smokers with schizophrenia treated with varenicline: A pilot study. Open Journal of Psychiatry, 2012, 02, 327-334.	0.6	1
80	No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients. Clinical Psychopharmacology and Neuroscience, 2012, 10, 49-53.	2.0	7
81	A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 273.	4.8	4
82	The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1022-1025.	4.8	59
83	Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan. Psychiatry Research, 2011, 186, 326-332.	3.3	29
84	Reliability, validity and clinical utility of a Japanese version of the Social Adaptation Selfâ€evaluation Scale as calibrated using the Beck Depression Inventory. Psychiatry and Clinical Neurosciences, 2011, 65, 624-629.	1.8	24
85	No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients. Human Psychopharmacology, 2011, 26, 348-351.	1.5	2
86	Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report. Human Psychopharmacology, 2011, 26, 531-534.	1.5	14
87	Effect of treatment with atypical drugs for 6 months on brain levels of N-acetyl aspartate or serum levels of brain-derived neurotrophic factor in early-stage first-episode schizophrenia - a preliminary study. Clinical Neuropsychopharmacology and Therapeutics, 2011, 2, 34-42.	0.3	0
88	Nonadherence to Paroxetine. Journal of Clinical Psychopharmacology, 2010, 30, 82-83.	1.4	4
89	Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Human Psychopharmacology, 2010, 25, 139-144.	1.5	35
90	Varenicline does not increase serum BDNF levels in patients with nicotine dependence. Human Psychopharmacology, 2010, 25, 276-279.	1.5	17

#	Article	IF	CITATIONS
91	No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations. Human Psychopharmacology, 2010, 25, 487-490.	1.5	3
92	Plasma levels of brainâ€derived neurotrophic factor and interleukinâ€6 in patients with dysthymic disorder: comparison with age―and sexâ€matched major depressed patients and healthy controls. Human Psychopharmacology, 2010, 25, 566-569.	1.5	27
93	Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. Journal of Psychopharmacology, 2010, 24, 1764-1771.	4.0	36
94	Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus. World Journal of Biological Psychiatry, 2010, 11, 121-128.	2.6	18
95	Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World Journal of Biological Psychiatry, 2010, 11, 256-261.	2.6	35
96	Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia. Schizophrenia Research, 2010, 116, 196-203.	2.0	62
97	Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 308-312.	4.8	42
98	No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1480-1483.	4.8	32
99	A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers. International Journal of Psychiatry in Clinical Practice, 2010, 14, 220-222.	2.4	20
100	A case of late-onset Tourette's disorder successfully treated with aripiprazole: View from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF). World Journal of Biological Psychiatry, 2009, 10, 977-980.	2.6	8
101	Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. International Journal of Psychiatry in Clinical Practice, 2009, 13, 21-24.	2.4	6
102	A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World Journal of Biological Psychiatry, 2009, 10, 620-622.	2.6	6
103	Serum levels of brainâ€derived neurotrophic factor in comorbidity of depression and alcohol dependence. Human Psychopharmacology, 2009, 24, 409-413.	1.5	37
104	Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Human Psychopharmacology, 2009, 24, 489-494.	1.5	23
105	Associations between plasma levels of 3â€methoxyâ€4â€hydroxyphenylglycol (MHPC) and negative symptoms or cognitive impairments in earlyâ€stage schizophrenia. Human Psychopharmacology, 2009, 24, 639-645.	1.5	21
106	Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 722-726.	4.8	176
107	Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: Comparison between milnacipran and paroxetine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1451-1453.	4.8	29
108	Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. World Journal of Biological Psychiatry, 2009, 10, 248-251.	2.6	4

#	Article	IF	CITATIONS
109	Olanzapine orally disintegrating tablets (Zyprexa Zydis ^R) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study. World Journal of Biological Psychiatry, 2009, 10, 741-745.	2.6	10
110	Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. Human Psychopharmacology, 2008, 23, 327-332.	1.5	7
111	Addition of risperidone to sertraline improves sertralineâ€resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. Human Psychopharmacology, 2008, 23, 707-713.	1.5	15
112	A case of vascular depression associated with musical hallucinations successfully treated with paroxetine and a low dose of risperidone. Psychogeriatrics, 2008, 8, 38-41.	1.2	5
113	Two cases of burning mouth syndrome treated with olanzapine. Psychiatry and Clinical Neurosciences, 2008, 62, 359-361.	1.8	28
114	Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 679-685.	4.8	79
115	Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1185-1190.	4.8	79
116	Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1034-1037.	4.8	155
117	Treatment with risperidone for 4Âweeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1072-1077.	4.8	53
118	Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Human Psychopharmacology, 2007, 22, 483-490.	1.5	7
119	Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa. Psychiatry and Clinical Neurosciences, 2007, 61, 452-452.	1.8	1
120	Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. International Clinical Psychopharmacology, 2007, 22, 21-7.	1.7	51
121	Effect of risperidone on plasma catecholamine metabolites and brainâ€derived neurotrophic factor in patients with bipolar disorders. Human Psychopharmacology, 2006, 21, 433-438.	1.5	48
122	Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World Journal of Biological Psychiatry, 0, , 1-6.	2.6	5